Emflaza
Deflazacort
Emflaza é um corticosteróide indicado para o tratamento da distrofia muscular de Duchenne (DMD) em pacientes com idade inferior a 5 anos e mais velhos.
more
Deflazacort tablets
What is this medicine?
Deflazacort a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older.
What should I tell my health care providers before I take this medicine?
They need to know if you have any of these conditions:
- Hypersensitivity to deflazacort;
- Alterations in Endocrine Function: Hypothalamic-pituitary-adrenal axis suppression, Cushing’s syndrome, and hyperglycemia;
- Immunosuppression and Increased Risk of Infection: Increased risk of new, exacerbation, dissemination, or reactivation of latent infections, which can be severe and at times fatal;
- Alterations in Cardiovascular/Renal Function: elevated blood pressure and sodium, and for decreased potassium level;
- Gastrointestinal Perforation: GI disorders;
- Behavioral and Mood Disturbances: euphoria, insomnia, mood swings, personality changes, severe depression, and psychosis;
- Effects on Bones: decreases in bone mineral density;
- Serious Skin Rashes;
- Ophthalmic Effects: May include cataracts, infections, and glaucoma;
- Vaccination: Do not administer live or live attenuated vaccines to patients receiving immunosuppressive doses of corticosteroids.
How should I use this medicine?
The recommended once-daily dosage is approximately 0.9 mg/kg/day administered orally. Discontinue gradually when administered for more than a few day..
What may interact with this medicine?
- Moderate or strong CYP3A4 inhibitors: Give one third of the recommended dosage;
- Avoid use of moderate or strong CYP3A4 inducers, as they may reduce efficacy.
What side effects may I notice from this medicine?
The most common adverse reactions are Cushingoid appearance, weight increased, increased appetite, upper respiratory tract infection, cough, pollakiuria, hirsutism, central obesity, and nasopharyngitis.
